SRC and non-small cell lung carcinoma: Altogether, these data suggest that the three compounds may act with different mechanisms in NSCLC cell lines: while dasatinib, as expected, functions exclusively via Src inhibition, saracatinib showed an additional mechanism of action based on a direct EGFR inhibition.